Cargando…

Primary small cell esophageal carcinoma, chemotherapy sequential immunotherapy: A case report

BACKGROUND: Primary small cell esophageal carcinoma (PSCEC) is aggressive and rare, with a worse prognosis than other subtypes esophageal carcinoma. No definitive and optimum standard guidelines are established for treating it. Herein, we report a case of PSCEC, including a current literature review...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Yong-Hui, Zhang, Kai, Chen, Hui-Guo, Wu, Wei-Bin, Li, Xiao-Jun, Zhang, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362569/ https://www.ncbi.nlm.nih.gov/pubmed/34435015 http://dx.doi.org/10.12998/wjcc.v9.i22.6478

Ejemplares similares

Sequential Cytokine-Induced Killer Cell Immunotherapy Enhances the Efficacy of the Gemcitabine Plus Cisplatin Chemotherapy Regimen for Metastatic Nasopharyngeal Carcinoma
por: Li, Yin, et al.
Publicado: (2015)

Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma
por: Wu, Zhigang, et al.
Publicado: (2021)

Safety and Feasibility of Esophagectomy Following Neoadjuvant Immunotherapy Combined with Chemotherapy for Esophageal Squamous Cell Carcinoma
por: Gu, Yi-Min, et al.
Publicado: (2022)

Stratified treatment of localized cervical esophageal squamous cell carcinoma induced by neoadjuvant immunotherapy plus chemotherapy (SCENIC)
por: Li, Chunguang, et al.
Publicado: (2022)

Sequential boost of intensity‐modulated radiotherapy with chemotherapy for inoperable esophageal squamous cell carcinoma: A prospective phase II study
por: Fan, Xing‐Wen, et al.
Publicado: (2020)

Chemoimmunotherapy in advanced esophageal squamous cell carcinoma: optimizing chemotherapy regimens for immunotherapy combinations
por: Liu, Zhichao, et al.
Publicado: (2022)

Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: A propensity score matching
por: Jing, Shao-Wu, et al.
Publicado: (2022)

Immunotherapy with or without radiotherapy for metastatic or recurrent esophageal squamous cell carcinoma: A real-world study
por: Wu, Xiaoyue, et al.
Publicado: (2022)

METTL3 Is Associated With the Malignancy of Esophageal Squamous Cell Carcinoma and Serves as a Potential Immunotherapy Biomarker
por: Zhou, Yubin, et al.
Publicado: (2022)

Safety and Feasibility of Esophagectomy Following Combined Immunotherapy and Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Analysis
por: Hong, Zhi-Nuan, et al.
Publicado: (2022)

Endoscopic diagnosis of early-stage primary esophageal small cell carcinoma: Report of two cases
por: Er, Li-Mian, et al.
Publicado: (2021)

The Survival and Prognosis Characteristics of Primary Esophageal Small-Cell Carcinoma
por: Li, Jie, et al.
Publicado: (2022)

Second primary malignancy in patients with esophageal adenocarcinoma and squamous cell carcinoma
por: Zhang, Guoqing, et al.
Publicado: (2019)

Tumor-Infiltrating Immune Cells and PD-L1 as Prognostic Biomarkers in Primary Esophageal Small Cell Carcinoma
por: Wu, Xiao, et al.
Publicado: (2020)

Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer: A systematic review and meta-analysis
por: Liu, Yunsong, et al.
Publicado: (2023)

Immunotherapy for Esophageal Squamous Cell Carcinoma
por: Kojima, Takashi, et al.
Publicado: (2017)

Treatment beyond progression with chemo-immunotherapy in an advanced esophageal squamous cell carcinoma patient: a case report
por: Peng, Ping, et al.
Publicado: (2021)

Immunotherapy combined with chemotherapy in the treatment for rare primary mucoepidermoid carcinoma of the liver: a case report
por: Deng, Linghui, et al.
Publicado: (2023)

Neoadjuvant immunotherapy for resectable esophagal squamous cell carcinoma: An ace up the sleeve
por: Zhou, Qing, et al.
Publicado: (2023)

Short-term outcome of neoadjuvant immunotherapy and chemotherapy in non–small cell lung cancer: A systematic review and meta-analysis
por: Zhang, Chao, et al.
Publicado: (2021)

A three-protein signature and clinical outcome in esophageal squamous cell carcinoma
por: Cao, Hui-Hui, et al.
Publicado: (2014)

Perioperative immunotherapy for esophageal squamous cell carcinoma: Now and future
por: Liu, Yong
Publicado: (2023)

Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer
por: Sun, Sheng-Jie, et al.
Publicado: (2022)

Late development of esophageal stricture following radiation and chemotherapy for small cell carcinoma of the lung: A case report
por: Zhang, Michael A, et al.
Publicado: (2008)

Esophageal fistula after definitive concurrent chemotherapy and intensity modulated radiotherapy for esophageal squamous cell carcinoma
por: Pao, Tzu-Hui, et al.
Publicado: (2021)

Role of ferroptosis in esophageal cancer and corresponding immunotherapy
por: Fan, Xin, et al.
Publicado: (2023)

P1195: A PROSPECTIVE STUDY OF TARGETED SEQUENTIAL IMMUNOTHERAPY. IN PATIENTS WITH RELAPSED REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA.
por: Guo, Yuelu, et al.
Publicado: (2023)

A Molecular Prognostic Model Predicts Esophageal Squamous Cell Carcinoma Prognosis
por: Cao, Hui-Hui, et al.
Publicado: (2014)

Perioperative outcomes of neoadjuvant immunotherapy plus chemotherapy and neoadjuvant chemoradiotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective comparative cohort study
por: Zhang, Hai, et al.
Publicado: (2023)

Case Report: Sequential Chemotherapy and Immunotherapy Produce Sustained Response in Osteosarcoma With High Tumor Mutational Burden
por: Zheng, Shuier, et al.
Publicado: (2021)

Gastrointestinal-type chemotherapy prolongs survival in an atypical primary ovarian mucinous carcinoma: A case report
por: Wang, Qi, et al.
Publicado: (2021)

Predicting response to immunotherapy plus chemotherapy in patients with esophageal squamous cell carcinoma using non-invasive Radiomic biomarkers
por: Zhu, Ying, et al.
Publicado: (2021)

Is adjuvant immunotherapy a new standard for non‐pathological complete response patients with resectable esophageal squamous cell carcinoma?
por: Wang, Jun, et al.
Publicado: (2022)

Successful chemotherapy with continuous immunotherapy for primary pulmonary endovascular epithelioid hemangioendothelioma: A case report
por: Guo, Wenliang, et al.
Publicado: (2023)

Tumor‐infiltrating CD8(+) T cell is prognostic and predicts adjuvant chemotherapy benefit in patients with limited‐stage small cell esophageal carcinoma
por: Zhang, Zhihui, et al.
Publicado: (2021)

Self-renewal and chemotherapy resistance of p75(NTR )positive cells in esophageal squamous cell carcinomas
por: Huang, Sheng-Dong, et al.
Publicado: (2009)

The predictive value of histological tumor regression grading (TRG) for therapeutic evaluation in locally advanced esophageal carcinoma treated with neoadjuvant chemotherapy
por: Guo, Kang, et al.
Publicado: (2012)

Histology transformation-mediated pathological atypism in small-cell lung cancer within the presence of chemotherapy: A case report
por: Ju, Qing, et al.
Publicado: (2021)

Multimodality therapy is recommended for limited-stage combined small cell esophageal carcinoma
por: Wang, Huan-Huan, et al.
Publicado: (2015)

Cost-Effectiveness of Nivolumab Immunotherapy vs. Paclitaxel or Docetaxel Chemotherapy as Second-Line Therapy in Advanced Esophageal Squamous Cell Carcinoma in China
por: Lin, Ying-tao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b2d9stnbon755ioeqaa5t279nm